Jasper Therapeutics Inc.-CW26JSPRWPreferred / convertible
13F holders, Q4 2024 (December 31)5holders
1new positions
0sold out
$0.21avg. 13F price*
At the end of Q4 2024, 5 institutions reported holding Jasper Therapeutics Inc.-CW26 (JSPRW) in their 13F filings, unchanged from Q3 2024. 1 opened new positions and 0 sold out. The largest holders were Walleye Capital LLC ($120K), TENOR CAPITAL MANAGEMENT Co., L.P. ($52K) and Zazove Associates LLC ($12K).
- Company
- Jasper Therapeutics Inc.-CW26
- CUSIP
- 471871111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $437 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 23,615 shares bought and 22,374 shares sold, net +1,241 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Walleye Capital LLC | — | Reduce -3.8% | 573,640 | $120K |
| TENOR CAPITAL MANAGEMENT Co., L.P. | — | No change | 250,000 | $52K |
| Zazove Associates LLC | — | No change | 65,456 | $12K |
| Walleye Trading LLC | — | Add +149.3% | 35,138 | $7K |
| UBS Group AG | — | New | 2,572 | $437 |
"% of holder's portfolio" is JSPRW's weight in each manager's 13F, not the share of Jasper Therapeutics Inc.-CW26 the manager owns.